Business Context and Reporting Period
Company: Kewaunee Scientific Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: April 30, 2010
Business Overview: The Company designs, manufactures, and installs laboratory and technical furniture, including cabinetry, fume hoods, and workstations. Products are sold primarily to pharmaceutical, biotechnology, educational, and healthcare sectors through dealers, agents, and a national distributor. Operations are segmented into Domestic and International divisions.
Key Financial Metrics
| Metric ($ in thousands) | Fiscal 2010 | Fiscal 2009 |
|---|---|---|
| Net Sales | $99,093 | $103,978 |
| Gross Profit | $21,403 | $21,373 |
| Gross Margin | 21.6% | 20.6% |
| Operating Earnings | $5,827 | $7,084 |
| Net Earnings (Attributable to Kewaunee) | $3,572 | $4,247 |
| Diluted EPS | $1.39 | $1.66 |
| Cash from Operating Activities | $4,533 | $2,100 |
| Capital Expenditures | $4,239 | $1,500 |
| Short-term Borrowings | $4,872 | $5,720 |
| Long-term Debt | $5,073 | $6,141 |
| Working Capital | $20,085 | $18,882 |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 4.7% to $99.1 million. Domestic sales fell 3.0% due to deferred orders from small/mid-sized projects during the recession. International sales dropped 16.0% to $11.5 million, though late-year quotation activity suggested recovery.
- Margin Expansion: Gross profit margin improved to 21.6% from 20.6%, driven by raw material sourcing alternatives, cost improvements, and manufacturing efficiencies.
- Operating Expenses: Increased to $15.6 million (15.7% of sales) from $14.3 million. The rise was primarily due to a $1.0 million increase in pension expense (linked to prior year investment declines) and higher sales/marketing costs, partially offset by reduced performance incentive compensation.
- Profitability: Net earnings attributable to the Company declined 15.9% to $3.57 million ($1.39 per share) compared to $4.25 million ($1.66 per share) in the prior year.
- Order Backlog: Increased to $68.9 million at April 30, 2010, from $62.7 million the prior year. Approximately 70% is expected to ship in fiscal 2011.
Guidance, Outlook, and Risks
- Outlook: Management expects fiscal 2011 to be profitable but cites uncertainty regarding the timing and strength of the global economic recovery. Demand remains dependent on laboratory construction projects.
- Capital Expenditures: Fiscal 2011 capital expenditures are anticipated to be approximately $5.5 million, primarily for the completion of Statesville facility expansion, funded by long-term bank financing.
- Dividends: Cash dividends of $0.38 per share were paid in fiscal 2010. Future dividends are expected to align with operating results.
- Key Risks:
- Economic Conditions: Volatility in financial markets and recessionary pressures may delay customer projects.
- Raw Material Costs: The Company bears the burden of cost increases for steel, wood, and resin between order quotation and delivery due to firm-price quoting practices.
- Customer Concentration: Sales to national distributor VWR International, LLC represented approximately 10% of total sales in fiscal 2010.
- Construction Delays: Revenue recognition is often delayed by construction timelines outside the Company's control.
Investor Verification Checklist
- Backlog Conversion: Verify the actual shipment rate of the $68.9 million backlog in fiscal 2011, noting the risk of customer rescheduling.
- Cost Pass-Through: Monitor the Company's ability to pass increased raw material costs (steel, wood) to customers without losing bid competitiveness.
- Pension Liability: Review the funded status of the defined benefit pension plan, which showed an underfunded status of $2.665 million and requires a projected contribution of $672,000 in fiscal 2011.
- International Recovery: Assess whether the late-fiscal 2010 increase in international quotation activity translates into sustained revenue growth in fiscal 2011.
- Debt Covenants: Confirm continued compliance with financial covenants on the $14 million revolving credit facility, specifically debt-to-net worth and fixed charge coverage ratios.